Nasdaq · CIK 0001774857
AARD Aardvark Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 4 d ago. Close $4.76 on Oct 9, 2026, +37% from the 52-week low and -71% from the high.
Last 90 days
Net insider value
-$395k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$395k by 1 insider
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
AARDOct 9, 2026 · close 4.76
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Aardvark Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 31Weak | Nelson Sun See Remarks sell | $395k 76,754 shares | -68% | - | |
| 43Moderate | Tien-Li Lee Chief Executive Officer buy | $101k 7,000 shares | +0% | +123% from low-10% from high | |
| 36Weak | Nelson Sun Chief Financial Officer buy | $43k 3,000 shares | +3% | +123% from low-10% from high | |
| 51Moderate | Tien-Li Lee Chief Executive Officer buy | $97k 10,000 shares | +1% | +42% from low-42% from high | |
| 52Moderate | Tien-Li Lee Chief Executive Officer buy | $161k 20,000 shares | +1% | +14% from low-54% from high | |
| 48Moderate | Nelson Sun Chief Financial Officer buy | $48k 6,000 shares | +6% | +13% from low-54% from high | |
| 54Moderate | Cormorant Asset Management, LP other buy | $3.0M 187,500 shares | +23% | - | |
| 51Moderate | Nelson Sun Chief Financial Officer buy | $160k 10,000 shares | +11% | - | |
| 53Moderate | Tien-Li Lee Chief Executive Officer buy | $265k 16,542 shares | +1% | - | |
| 57Moderate | Decheng Capital Global Life Sciences Fund IV, L.P. owner buy | $20M 1,250,000 shares | +54% | - |
Transactions
The last 46 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 7, 2026 | Zhongwei Zhang director | AGrant or award Stock Option (right to buy)derivative | +127,061 | $0.00 | $0 | 127,061 | 4 d ago |
| Sep 10, 2026 | Nelson Sun See Remarks | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -14,754 | $5.00 | $74k | 97,475 | 31 d ago |
| Sep 11, 2026 | Nelson Sun See Remarks | SOpen-market sale Common Stock, par value $0.00001 per share10b5-1 | -62,000 | $5.18 | $321k | 35,475 | 31 d ago |
| Dec 11, 2025 | Tien-Li Lee Chief Executive Officer | POpen-market purchase Common Stock | +7,000 | $14.49 | $101k | 1,551,613 | Dec 12, 2025 |
| Dec 11, 2025 | Nelson Sun Chief Financial Officer | POpen-market purchase Common Stock | +3,000 | $14.40 | $43k | 108,484 | Dec 12, 2025 |
| Oct 15, 2025 | Bryan Jones Chief Operating Officer | MOption exercise Common Stock | +1,250 | $4.24 | $5,300 | 1,250 | Oct 16, 2025 |
| Oct 15, 2025 | Tien-Li Lee Chief Executive Officer | MOption exercise Common Stock | +1,229 | $4.24 | $5,211 | 1,544,613 | Oct 16, 2025 |
| Oct 15, 2025 | Bryan Jones Chief Operating Officer | MOption exercise Stock option (right to buy)derivative | -1,250 | $0.00 | $0 | 40,052 | Oct 16, 2025 |
| Oct 15, 2025 | Tien-Li Lee Chief Executive Officer | MOption exercise Stock option (right to buy)derivative | -1,229 | $0.00 | $0 | 40,566 | Oct 16, 2025 |
| Sep 15, 2025 | Tien-Li Lee Chief Executive Officer | POpen-market purchase Common Stock | +6,500 | $9.51 | $62k | 1,539,884 | Sep 16, 2025 |
| Sep 15, 2025 | Tien-Li Lee Chief Executive Officer | POpen-market purchase Common Stock | +3,500 | $9.94 | $35k | 1,543,384 | Sep 16, 2025 |
| Sep 10, 2025 | Tien-Li Lee Chief Executive Officer | POpen-market purchase Common Stock | +9,000 | $7.91 | $71k | 1,522,384 | Sep 12, 2025 |
| Sep 11, 2025 | Tien-Li Lee Chief Executive Officer | POpen-market purchase Common Stock | +6,000 | $7.82 | $47k | 1,528,384 | Sep 12, 2025 |
| Sep 12, 2025 | Tien-Li Lee Chief Executive Officer | POpen-market purchase Common Stock | +5,000 | $8.50 | $43k | 1,533,384 | Sep 12, 2025 |
| Sep 9, 2025 | Nelson Sun Chief Financial Officer | POpen-market purchase Common Stock | +6,000 | $8.07 | $48k | 105,484 | Sep 10, 2025 |
| Aug 28, 2025 | Tien-Li Lee Chief Executive Officer | MOption exercise Common Stock | +17,209 | $4.24 | $73k | 1,513,384 | Aug 29, 2025 |
| Aug 28, 2025 | Tien-Li Lee Chief Executive Officer | MOption exercise Stock option (right to buy)derivative | -17,209 | $0.00 | $0 | 41,795 | Aug 29, 2025 |
| Jun 11, 2025 | Tien-Li Lee Chief Executive Officer | AGrant or award Stock option (right to buy)derivative | +549,534 | $0.00 | $0 | 549,534 | Jun 13, 2025 |
| Jun 11, 2025 | Jeffrey Chi director | AGrant or award Stock Option (right to buy)derivative | +61,017 | $0.00 | $0 | 61,017 | Jun 13, 2025 |
| Jun 11, 2025 | Manasi Jaiman Chief Medical Officer | AGrant or award Stock Option (right to buy)derivative | +126,999 | $0.00 | $0 | 126,999 | Jun 13, 2025 |
| Jun 11, 2025 | Nelson Sun Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +209,826 | $0.00 | $0 | 209,826 | Jun 13, 2025 |
| Jun 11, 2025 | Victor Edward Tong Jr director | AGrant or award Stock Option (right to buy)derivative | +61,017 | $0.00 | $0 | 61,017 | Jun 13, 2025 |
| Jun 11, 2025 | Bryan Jones Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +122,033 | $0.00 | $0 | 122,033 | Jun 13, 2025 |
| Jun 11, 2025 | Susan E Graf director | AGrant or award Stock Option (right to buy)derivative | +30,508 | $0.00 | $0 | 30,508 | Jun 13, 2025 |
| Jun 11, 2025 | Roy D. Baynes director | AGrant or award Stock Option (right to buy)derivative | +30,508 | $0.00 | $0 | 30,508 | Jun 13, 2025 |
| Feb 14, 2025 | Cormorant Asset Management, LP other | CConversion Common Stockindirect: See Footnote | +800,189 | - | - | 800,189 | Feb 19, 2025 |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. owner | CConversion Common Stockindirect: By Decheng Capital Global Life Sciences Fund IV, L.P. | +2,333,887 | - | - | 2,333,887 | Feb 19, 2025 |
| Feb 14, 2025 | Nelson Sun Chief Financial Officer | CConversion Common Stock | +7,001 | - | - | 89,484 | Feb 19, 2025 |
| Feb 14, 2025 | Jeffrey Chi director | CConversion Common Stockindirect: By Vickers Venture Co-investment LLC | +133,364 | - | - | 133,364 | Feb 19, 2025 |
| Feb 14, 2025 | Tien-Li Lee Chief Executive Officer | CConversion Common Stock | +41,303 | - | - | 1,479,633 | Feb 19, 2025 |
| Feb 14, 2025 | Vickers Venture Fund VI Pte Ltd owner | CConversion Common Stockindirect: By Vickers Venture Fund VI Pte. Ltd. | +1,637,411 | - | - | 1,637,411 | Feb 19, 2025 |
| Feb 14, 2025 | Tien-Li Lee Chief Executive Officer | POpen-market purchase Common Stock | +16,542 | $16.00 | $265k | 1,496,175 | Feb 19, 2025 |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. owner | CConversion Common Stockindirect: By Decheng Capital Global Healthcare Fund (Master), LP | +333,412 | - | - | 333,412 | Feb 19, 2025 |
| Feb 14, 2025 | Jeffrey Chi director | CConversion Series C Convertible Preferred Stockderivativeindirect: By Vickers Venture Co-investment LLC | -1,130,135 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | Vickers Venture Fund VI Pte Ltd owner | CConversion Common Stockindirect: By Vickers Venture Fund VI Pte. Ltd. | +413,491 | - | - | 2,050,902 | Feb 19, 2025 |
| Feb 14, 2025 | Nelson Sun Chief Financial Officer | POpen-market purchase Common Stock | +10,000 | $16.00 | $160k | 99,484 | Feb 19, 2025 |
| Feb 14, 2025 | Cormorant Asset Management, LP other | POpen-market purchase Common Stockindirect: See Footnote | +187,500 | $16.00 | $3.0M | 987,689 | Feb 19, 2025 |
| Feb 14, 2025 | Vickers Venture Fund VI Pte Ltd owner | CConversion Series A Convertible Preferred Stockderivativeindirect: By Vickers Venture Fund VI Pte. Ltd. | -13,875,429 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | Nelson Sun Chief Financial Officer | CConversion Series C Convertible Preferred Stockderivative | -59,332 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | Cormorant Asset Management, LP other | CConversion Series C Convertible Preferred Stockderivativeindirect: See Footnotes | -6,780,810 | - | - | 0 | Feb 19, 2025 |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. owner | POpen-market purchase Common Stockindirect: By Decheng Capital Global Life Sciences Fund IV, L.P. | +625,000 | $16.00 | $10M | 2,958,887 | Feb 19, 2025 |
| Feb 14, 2025 | Tien-Li Lee Chief Executive Officer | CConversion Series A Convertible Preferred Stockderivative | -350,002 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. owner | POpen-market purchase Common Stockindirect: By Decheng Capital Global Healthcare Fund (Master), LP | +625,000 | $16.00 | $10M | 958,412 | Feb 19, 2025 |
| Feb 14, 2025 | Vickers Venture Fund VI Pte Ltd owner | CConversion Series B Convertible Preferred Stockderivativeindirect: By Vickers Venture Fund VI Pte. Ltd. | -3,503,919 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. owner | CConversion Series C Convertible Preferred Stockderivativeindirect: By Decheng Capital Global Life Sciences Fund IV, L.P. | -19,777,363 | $0.00 | $0 | 0 | Feb 19, 2025 |
| Feb 14, 2025 | Decheng Capital Global Life Sciences Fund IV, L.P. owner | CConversion Series C Convertible Preferred Stockderivativeindirect: By Decheng Capital Global Healthcare Fund (Master), LP | -2,825,337 | $0.00 | $0 | 0 | Feb 19, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Roy D. Baynesdirector
- Jeffrey Chidirector
- Cormorant Asset Management, LPowner, other
- Decheng Capital Global Life Sciences Fund IV, L.P.owner
- Susan E Grafdirector
- Manasi JaimanChief Medical Officer
- Bryan JonesChief Operating Officer
- Tien-Li LeeChief Executive Officer
- Nelson SunChief Financial Officer
- Victor Edward Tong Jrdirector
- Vickers Venture Fund VI Pte Ltdowner
- Zhongwei Zhangdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.